He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...

Biogen’s 4 nominations in the Pharma category for its Friedreich’s ataxia work included 3 in the “direct-to-patient ads for ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

The cumulative data from the Phase 1 study indicate that salanersen has a generally well tolerated safety profile at both the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in ...

Biogen Inc. closed 46.93% short of its 52-week high of $238.00, which the company achieved on July 12th.

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

Shares of Biogen Inc. BIIB slipped 1.79% to $124.76 Monday, on what proved to be an all-around positive trading session for ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.